11/14/2012 7:25:21 AM
FORT LAUDERDALE, Fla., Nov. 14, 2012 (GLOBE NEWSWIRE) -- MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that markets its RIO® Robotic Arm Interactive Orthopedic surgical platform, MAKOplasty® joint specific applications and proprietary RESTORIS® implants that together enable orthopedic surgeons to consistently, reproducibly and precisely treat patient specific osteoarthritic disease, today announced the pricing of its previously announced underwritten public offering. Pursuant to the offering, MAKO has sold 3,042,000 shares of its common stock at a public offering price of $13.15 per share. In connection with the offering, MAKO has also granted the underwriter a 30-day option to purchase up to an additional 456,300 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. acted as the sole manager for the offering. Moelis & Company acted as financial advisor to MAKO.
comments powered by